Nanobiotix (NASDAQ:NBTX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08, FiscalAI reports. The company had revenue of $3.17 million during the quarter, compared to the consensus estimate of $1.73 million.
Nanobiotix Trading Down 5.1%
NBTX traded down $1.78 during trading on Thursday, reaching $33.46. 203,059 shares of the company traded hands, compared to its average volume of 88,895. Nanobiotix has a 12-month low of $14.46 and a 12-month high of $57.14. The firm has a fifty day simple moving average of $38.90 and a 200 day simple moving average of $37.40.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on NBTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Guggenheim started coverage on Nanobiotix in a report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price target for the company. Finally, Leerink Partners lifted their price target on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.
Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.
Recommended Stories
- Five stocks we like better than Nanobiotix
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
